ANDA 78807, held by Ipca Laboratories. Metoclopramide Hydrochloride.
As of Nov 21, 2026, ANDA 78807 (Metoclopramide Hydrochloride), held by Ipca Laboratories, was first approved by FDA on Jun 12, 2008, with 7 approved supplements and 0 published complete response letters.
Metoclopramide tablets are indicated for the: Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. Relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Limitations of Use: Metoclopramide tablets are not recommended for use in pediatric patients due to the risk of tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates. ( 1, 8.4 )
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 12, 2008 | Original application | Approved | None posted |
| Metoclopramide HydrochlorideEQ 5MG BASE · tablet;oral | Metoclopramide Hydrochloride | Rx |
| Metoclopramide HydrochlorideEQ 10MG BASE · tablet;oral | Metoclopramide Hydrochloride | Rx |
| Aug 1, 2025 | Supplement 13Labeling · Standard review | Approved | None posted |
| Aug 1, 2025 | Supplement 14Labeling · Standard review | Approved | None posted |
| Apr 5, 2019 | Supplement 10Labeling · Standard review | Approved | None posted |
| Mar 8, 2012 | Supplement 8Labeling | Approved | None posted |
| Feb 21, 2012 | Supplement 6Labeling | Approved | None posted |
| Mar 31, 2010 | Supplement 3Labeling | Approved | None posted |
| Dec 1, 2009 | Supplement 2Labeling | Approved | None posted |
| Jun 12, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters